Navigation Links
Study measures single-molecule machines in action
Date:7/6/2010

In the development of future molecular devices, new display technologies, and "artificial muscles" in nanoelectromechanical devices, functional molecules are likely to play a primary role.

Rotaxanes, one family of such molecules, are tiny, mechanically interlocked structures that consist of a dumbell-shaped molecule whose rod section is encircled by a ring. These structures behave as molecular "machines," with the ring moving along the rod from one station to another when stimulated by a chemical reaction, light or acidity.

To realize the potential of these molecular machines, however, it is necessary to understand and to measure their function at the nanoscale. Previous methods for observing their operation have involved chemical measurements in solution and studying collections of them attached to surfaces, but neither has provided an accurate picture of their function in environments that are relevant to molecular-device operation.

Now, a multidisciplinary team of researchers from UCLA, Northwestern University, UC Merced, Pennsylvania State University and Japan has succeeded in observing single-molecule interactions of bistable rotaxanes functioning in their native environment.

The team's findings are published in the current edition of the journal ACS Nano.

Led by Paul Weiss from UCLA and Fraser Stoddart from Northwestern University, the team developed a molecular design that firmly attached rotaxanes to a surface, enabling them to be individually examined in their native environment by a scanning tunneling microscope (STM). Using this technology, the researchers were able to record station changes by the rotaxanes' rings along their rods in response to electrochemical signals.

Previously, rotaxanes had to be grouped for study because of their mobility and flexibility when attached to surfaces. And because STM instruments utilize an atomically thin tip to feel out nanoscale surfaces ― in much the same way a blind person reads Braille ― the rotaxanes' flexible nature made it difficult to study them individually. The research team's molecular design, however, helped significantly reduce this flexibility.

The STM developed by the team enables much more detailed studies of molecular machines, leading to greater understanding of how they interact with their neighbors and how they might work together in nanoelectromechanical devices.


'/>"/>

Contact: Mike Rodewald
mrodewald@cnsi.ucla.edu
310-267-5883
University of California - Los Angeles
Source:Eurekalert

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):